Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes View HTML
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis View HTML
Toggle Summary Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease View HTML
Toggle Summary Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid View HTML
Toggle Summary Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL
Company Also Presents Data on Novel Dual FXR/TGR5 Agonist INT-767
View HTML
Toggle Summary Intercept Pharmaceuticals Raises $25 Million Series B Financing
Dr. Lorenzo Tallarigo Appointed Chairman
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment of Primary Biliary Cirrhosis View HTML
Toggle Summary Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
Company to Present Data at EASD Plenary Session
View HTML
Toggle Summary Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity View HTML
Toggle Summary Nature Publication Reports on Key Roleof Bile Acids in Glucose Metabolism and Insulin Signaling View HTML